Board and management of 2cureX exercise all held warrants of series TO1 for SEK 6.04 million

April 26 | 2021
Board members and management in 2cureX AB (”2cureX” or the “Company”) have exercised all of their warrants of series TO1, which were issued in connection with the Company’s directed issue during the third quarter of 2020. The subscription period for TO1 began today, April 26, 2021, and lasts until May 7, 2021.

The warrant holders have the right for each owned warrant of series TO1 to subscribe to one (1) new share in 2cureX to a price of 13.22 per share. The number of warrants of series TO1 that has been exercised by board and management in the Company amounts to 457,018 warrants, corresponding 457,018 new shares to a value of SEK 6,041,777.96. Board and management exercise their warrants of series TO1 as follows:

Ole Thastrup, Chief Science Officer:

Exercise 377 830 TO1, corresponding SEK 4,994,912.60

Grith Hagel, Chief Operating Officer

Exercise 61 974 TO1, corresponding SEK 819,296.28

Henrik Harling, Chief Medical Officer

Exercise 2 343 TO1, corresponding SEK 30,974.46

Maarten van der Linden, Chief Business Officer

Exercise 746 TO1, corresponding SEK 9,862.12

Povl-André Bendz, Chairman

Exercise 9 496 TO1, corresponding SEK 125,537.12

Camilla Huse Bondesson, Board member

Exercise 3 347 TO1, corresponding SEK 44,247.34

Jørgen Drejer, Board member

Exercise 1 282 TO1, corresponding SEK 16,948.04

Summarized terms for the warrants of series TO1:

Subscription period: April 26 – May 7, 2021.

Issue size: 2,455,000 warrants of series TO1, which entitles to subscription of 2,455,000 shares. If all the warrants are exercised, The Company will receive approximately SEK [•] million before issuing costs.

Exercise price: SEK 13.22 per share.

Last day for trading warrants of series TO1: May 5, 2021.

Dilution etc.: If all warrants are exercised the share capital will increase with SEK 245,500, from SEK 1,484,600, to SEK 1,730,100. If all warrants are exercised the number of shares will increase with 2,455,000 shares, from 14,846,000 shares, to 17,301,000 shares. The dilution at exercise of all warrants amounts to 14.19 percent of the number of shares and 14.19 percent of the number of votes.

Note that the warrants that are not exercised at the latest May 7, 2021, or sold at the latest May 5, 2021, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.

How warrants are exercised:

Nominee-registered warrants (Custody account)

Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.

Direct-registered warrants (Securities account)

No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form.

The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.

The application form including instructions for payment will be available at 2cureX’s website, and on Mangold Fondkommission AB’s website,


Mangold Fondkommission AB is financial adviser and Eversheds Sutherland Advokatbyrå AB is legal advisor to 2cureX regarding the warrants.

For questions regarding the warrants, please contact:

Mangold Fondkommission AB

Tel: +46 8 5030 1595


For more information regarding 2cureX, please contact:
Fernando Andreu
Chief Executive Officer
Tel: +45 22 79 53 99

Certified Adviser

Redeye AB

Phone: +46 8 121 576 90


About 2cureX

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D microtumors that functionally resemble the patient's tumor and identifies the approved cancer treatment that most effectively kills the patient's tumor. Immediately after the test, the patient is given the selected treatment.

The first IndiTreat® product in metastatic colorectal cancer is introduced to the European market. Subsequent products help patients at different stages of colorectal cancer and other solid cancers.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit